pTeroBlue Pterostilbene + Resveratrol Blueberry Complex 350 mg
Genceutic Naturals' pTeroBlue Pterostilbene + Resveratrol Blueberry Complex is an 'Other Combinations' product in the Longevity & NAD+ category, formulated with antioxidant compounds. Each two-capsule serving contains 250mg of Japanese Knotweed extract (providing resveratrol), 50mg of pTeroPure trans-Pterostilbene, and 50mg of AuroraBlue Wild Alaska Blueberry Proprietary Blend. While these ingredients are recognized for their antioxidant potential, specific clinical dosing information for this combination is not provided, making it difficult to assess efficacy against research. The product receives an N+ Score of 54, earning an 'F' grade, placing it in the below-average tier. With three active ingredients, its label transparency is good. This supplement may appeal to those interested in a blend of traditional longevity compounds.
About This Product
pTeroBlue Pterostilbene + Resveratrol Blueberry Complex 350 mg by Genceutic Naturals is a longevity & nad+ supplement containing 3 active ingredients. It has earned an N+ Score of 54/100 (Grade F).
N+ Score Breakdown
Are key ingredients present at clinically effective doses based on research?
Does the product include all expected ingredients for its supplement category?
Are individual ingredient amounts clearly disclosed without proprietary blends?
Does the formula include a breadth of beneficial compounds from multiple pathways?
Strengths
- +Fully transparent label with individual ingredient amounts disclosed
- +Broad ingredient diversity exceeding category norms
Weaknesses
- −Missing several expected ingredients for its category
Ingredient Analysis (3 ingredients)
| Ingredient | Amount | Dose Adequacy |
|---|---|---|
| Japanese Knotweed (Polygonum cuspidatum) (root) extract | 250.000 mg | N/A |
| pTeroPure trans-Pterostilbene | 50.000 mg | N/A |
| AuroraBlue Wild Alaska Blueberry Proprietary Blend | 50.000 mg | N/A |
Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.